DNA Binding Provides a Molecular Strap Activating the Adenovirus Proteinase*\([5]

Sayan Gupta‡, Walter F. Mangel§, William J. McGrath§, Jennifer L. Perek§, Donna W. Lee§, Keiji Takamoto‡, and Mark R. Chance‡¶

Human adenovirus proteinase (AVP) requires two cofactors for maximal activity: pVlc, a peptide derived from the C terminus of adenovirus precursor protein pVI, and the viral DNA. Synchrotron protein footprinting was used to map the solvent accessible cofactor binding sites and to identify conformational changes associated with the binding of cofactors to AVP. The binding of pVlc alone or pVlc and DNA together to AVP triggered significant conformational changes adjacent to the active site cleft sandwiched between the two AVP subdomains. In addition, upon binding of DNA to AVP, it was observed that specific residues on each of the two major subdomains were significantly protected from hydroxyl radicals. Based on the locations of these protected side-chain residues and conserved aromatic and positively charged residues within AVP, a three-dimensional model of DNA binding was constructed. The model indicated that DNA binding can alter the relative orientation of the two AVP domains leading to the partial activation of AVP by DNA. In addition, both pVlc and DNA may independently alter the active site conformation as well as drive it cooperatively to fully activate AVP.

The location of the pVlc binding site on AVP is known; the mode of DNA binding is unknown. The crystal structure of AVP bound to the pVlc peptide is shown in Fig. 1a (7, 11). The structure has two major domains, with the active site sandwiched between the domains. The pVlc cofactor interacts with both domains forming an antiparallel β-sheet with strand 5 of domain 1, while its N terminus interacts with strand 7 from domain 2. Biochemical studies show that DNA binding is not sequence-specific (5); both electrostatic and nonelectrostatic forces are important to binding (8). Fig. 1b depicts the surface charge distribution on AVP; positively charged clusters are seen that may be involved in nonspecific DNA binding (10, 11).

This work defines a three-dimensional model of DNA binding to AVP. This was accomplished by using hydroxyl radical mediated protein footprinting to probe the specific interactions of AVP with its cofactors (12, 13). AVP was irradiated with white synchrotron x-ray radiation and reactive surface-exposed amino acid residues became oxidized. The experiment was then repeated but with cofactors bound to AVP. The observation of robust protections located adjacent to conserved, positively charged, and aromatic residues on the AVP surface suggested specific sites that are involved in contacting DNA (12–14). Also, cofactor-induced conformational changes adjacent to the active site are detected indicative of the molecular mechanisms of cofactor-induced protease activation (15–17).

EXPERIMENTAL PROCEDURES

Biochemicals and Synchrotron Exposures—pVlc (GVQSLKRRRCF) was purchased from Research Genetics (Huntsville, AL), and 12-mer...
single-stranded DNA (ssDNA) (GACGACTAGGAT) was purchased from Life Technologies (Rockville, MD). AVP was purified as described previously (5, 18). The concentrations of AVP, pVIc, and DNA were measured as described previously (19, 20). Samples were exposed to white light x-rays from the National Synchrotron Light Source beamline X-28C at the Brookhaven National Laboratory (Upton, NY) as described and then frozen (12, 21–23).

**Complex Formation—** AVP and its binary complexes with pVIc or with DNA or the tertiary complex of AVP-pVIc-DNA were prepared to a final concentration of 10 μM in 10 mM cacodylate (pH 7.4) and then irradiated with synchrotron radiation for varying time intervals. Complexes with 12-mer ssDNA were formed by incubating 10 μM 12-mer ssDNA with 10 μM AVP. Because the $K_f$ for 12-mer ssDNA and AVP is 63 nM, at 10 μM, virtually all of the 12-mer ssDNA will be bound to AVP (8). The $K_f$ of pVIc for AVP is 4.4 μM (6). To ensure that at 10 μM, all of the pVIc will be bound to AVP, covalent complexes between AVP and pVIc were formed overnight at concentrations of 100 μM each, and the resultant AVP-pVIc covalent complexes diluted to 10 μM. Under the conditions in which the synchrotron footprinting were carried out, the binary complexes and the tertiary complex were fully active enzymatically (data not shown).

**Protease Digestion of AVP—** Trypsin (Promega, Madison, WI) or chymotrypsin (Roche, Indianapolis, IN) was added to radiolyzed and control protein samples to an enzyme: protein ratio of 1:40 (w/w) in the presence of 10% acetonitrile, 0.2 mM DTT and 0.1 μM CaCl$_2$. The samples were incubated at 37 °C for 12 h. The nine tryptic peptides from the digests of AVP, AVP-pVIc, AVP-DNA, and AVP-pVIc-DNA that have been identified by LC-ESI-MS are shown in Table I. In this table we include only the data for peptides where we have been able to collect high signal-to-noise dose response plots for multiple states of the AVP protein. Similarly, six chymotryptic peptides (16–21, 76–80, 126–129, 134–141, 142–147, and 159–167) were examined (Supplementary Table I); together these peptides cover nearly two-thirds of the sequence of AVP, which contains 204 amino acid residues.

**Chromatography and Mass Spectrometry—** The digested peptide samples were introduced into the ion source of the mass spectrometer via a Waters Alliance 2690 high pressure LC system (Waters Corp., Milford, MA) as described elsewhere (12, 23). MS data were acquired using a quadrupole ion trap mass spectrometer (ThermoFinnegan LCQ, ThermoFinnegan Inc., San Jose, CA) equipped with an electrospray ion source as previously described (12, 23). The oxidation products were quantitated using the peak intensities of the mass spectral signals. The fraction of peptide modified was determined from the ratio of the intensity under ion signals for the oxidized radiolytic products to the sum of those for the unoxidized peptides and the oxidized radiolytic products (12, 23). The oxidized radiolytic products include +14, +16, +32, and +48 Da species relative to the unmodified ions. The fraction unmodified peptide determined from the average value of duplicate experiments versus exposure times (a “dose response” plot) was fit to an exponential decay function with Origin version 6.1 (OriginLabs, Northampton, MA) to determine the rate of peptide modification. The Origin program, using 95% confidence limits of the fitting results, determined the reported errors of the rate data.

**Solvent Accessibility Calculations—** The solvent accessibilities of individual side chains in the AVP-pVIc were determined from the
DNA Provides a Molecular Strap Activating AVP

**TABLE I**

| Peptide and molecular weight | Peptide sequences and accessible surface area values (in Å²) of selected amino acid side chains | Modified amino acid residue(s) identified by MS/MS | Modification rate (s⁻¹) |
|-----------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------|------------------------|
| 1–9                         | M G S S E Q E L K                                                                               | 11M                                             | 11.2 ± 1.5             |
| 29–37                       | F P G F V S P H K                                                                               | 30P, 35P, 36H                                   | 1.2 ± 0.43             |
| 38–48                       | L A C A I V N T A G R                                                                           |                                                 | 0.82 ± 0.22            |
| 49–63                       | E T G G V H W M A F A W N P R                                                                 |                                                 | 1.6 ± 0.2              |
| 82–93                       | Q V Y Q F E Y S L L R                                                                            | 23, 29, 12                                     | 28.0 ± 2.0             |
| 95–103                      | S A I A S S P D R                                                                                | 42, 50                                          | ✓                     |
| 104–109                     | C I T L E K                                                                                     | 74, 35                                          | 30.7 ± 3.4             |
| 170–180                     | N Q E Q L Y S F L E R                                                                            | 0.22, 3.0                                      | 7.8 ± 1.4              |
| 181–186                     | H S P Y F R                                                                                     | 64, 73, 59, 0                                  | 4.25 ± 0.4             |

| AVP                          | AVP-DNA                                           | AVP-pVIc                                       | AVP-pVIc-DNA           |
|-------------------------------|---------------------------------------------------|------------------------------------------------|------------------------|
| 11M                           | 1.0 ± 0.1                                          |                                                 | 0.9 ± 0.09             |
| 30P, 35P, 36H                 | 0.82 ± 0.22                                       |                                                 | 0.7 ± 0.03             |
| 23, 29, 12                   |                                                   |                                                 | ✓                      |
| 74, 35                        | 30.7 ± 3.4                                        |                                                 | 13.1 ± 0.6             |
| 0.22, 3.0                    |                                                   |                                                 | ✓                      |
| 64, 73, 59, 0                 |                                                   |                                                 | ✓                      |


**RESULTS**

Hydroxyl Radical-mediated Protein Footprinting—AVP and AVP-DNA complexes were exposed to white synchrotron x-ray radiation for periods of 0–150 ms followed by digestion with proteases and separation of the fragments by reverse-phase LC. ESI-MS analysis of the resolved fragments allowed each to be specifically identified. The relative abundances of unmodified and modified peptide ions were calculated from the corresponding peak ion intensities as a function of time of exposure to the synchrotron x-ray beam (12, 22, 23). The fraction of unmodified peptide used in the “dose response” (1 – (modified peptide/(modified + unmodified))) was consistently calculated at all exposure times for free AVP as well as for its complexes. The dose-response curves are presented as unmodified fraction and plotted on a semilogarithmic scale versus exposure time. Representative data for tryptic peptides 82–93 and 49–63 derived from free AVP, its two binary complexes, and the ternary complex are shown in Fig. 2. Because of the constant concentration of hydroxyl radicals in the sample during exposure (12, 21–23), the modification reactions followed pseudo first-order kinetics; kinetic fits are shown as solid or dashed lines in Fig. 2. The use of the loss of unmodified fraction as the dependent variable and the con-

---

*Notes:

1. Rates are derived from data such as that shown in Fig. 2.
2. The potentially modifiable amino acids are shown in bold with calculated accessible surface area printed below for the free AVP structure (see “Experimental Procedures”).
3. The probe residues indicated by MS/MS spectra for free AVP. The residues that are not confirmed by MS/MS are shown within parentheses. They are likely to be the probe residues, having accessible surface area greater than 20 Å. These peptides are not detected.
4. More than 50% oxidized peptide was found without any exposure to the x-ray beam.

---

Crystal structure (11). The surface areas (in Å²) are shown in Table I as numbers below the one-letter amino acid codes for the various tryptic peptides. The solvent accessibilities of individual residues in AVP in the absence of cofactor were also determined from the crystal structure of the binary complex after deleting the pVIc coordinates from the Protein Data Bank (PDB) file (1AVP). The program GETAREA 1.1 (www.scsb.utmb.edu/cgi-bin/get_a_form.tcl) was used to calculate the solvent accessible surface area per residue from the PDB files (24).

Sequence Alignments—AVP protein sequences were retrieved from the National Center for Biotechnology Information Entrez protein sequence database using a Basic Local Alignment Search Tool against the Human Adenovirus type 2 AVP sequence (25). The sequences selected had e-values of <10⁻⁰⁶ and duplicated sequences were eliminated manually. A total of 26 sequences were chosen for subsequent multiple alignment with the program ClustalW (26) from the European Bioinformatics Institute ClustalW Web server (www.ebi.ac.uk/clustalw) using default parameters. The AVP precursor sequences were also retrieved and aligned, and then C-terminal pVIc peptide sequences were obtained and aligned. Conserved AVP and pVIc sequences were calculated from those alignments and visualized using WebLogo (27) Web server (weblogo.berkeley.edu/) and are shown in Supplementary Fig. 1.

Model Building—The model for the AVP-pVIc-DNA ternary complex was built in O (28), using the PDB coordinates of a 12-mer single-strand AACCGTGCCCTCA taken from the structure of a duplex DNA combined with the 1AVP coordinates (11). All the P-O5’ (α) and O3’-P (γ) torsion angles (30), most of the O5’-C5’ (β) torsion angles, and several C5’-C4’ (γ) and C3’-O3’ torsion angles were rotated to locate the DNA backbone near the predicted DNA binding regions as well as to adjust the rise per residue to a nearly maximally stretched configuration. Refinements were carried out to optimize the stereochemical parameters in the DNA backbone, using the standard O refinement library. Rotational isomers were evaluated for some of the basic side chain residues (those with high B factors in the crystallographic data) in the vicinity of the DNA binding region to bring them closer to the DNA phosphate groups as well as to adjust the rise per residue to a nearly maximally stretched configuration.

---
sistent adherence to first order behavior observed in the data indicated that the intact material was probed and that the radiolysis experiments report biologically relevant information. The rate constants for modification for all identified tryptic peptides of free AVP and its complexes with cofactors are listed in Table I.

Peptide 82–93 in free AVP had a modification rate of 1.2 s⁻¹ (Fig. 2). Upon binding to DNA, the modification rate decreased over 90% to 0.09 s⁻¹. Binding of pVIc slightly increased the modification rate, while in the ternary complex, as for the binary complex with DNA, the modification rate was reduced over 90%. Protections of this magnitude typically indicate the formation of a buried interface (12–14, 30). The inset to Fig. 2a shows the abundance of unoxidized and oxidized peptides in free AVP and the AVP-DNA complex as analyzed by the total ion current signal for a 100 ms exposure. The singly and doubly modified peptides were detected as doubly charged ions at 795.9 m/z and 803.9 m/z, respectively. Quantitation of the relative abundance of the peaks for the modified and unmodified peptides gave an extent of modified peptide of 20% in the absence of DNA, while in presence of DNA the extent of oxidation for the peptide was only 2%, at an exposure time of 100 ms.

For tryptic peptide 49–63 (Fig. 2b), the rate of modification in free AVP was 2.5 s⁻¹; when AVP binds DNA, the modification rate increased 2-fold, while it increased over 6-fold upon binding to pVIc (Fig. 2b, Table I). The rate of modification for the ternary complex was slightly less than for the AVP/pVIc binary complex but still increased over 5-fold compared with free AVP. The effects of pVIc binding on the solvent accessibility of probe residues in this region were striking, because the pVIc cofactor binds on the opposite side of D1 to peptide 49–63, which is within S2 and the loop between S2 and S3 (Fig. 1a). These data indicated allosteric communication between the cofactor binding site and the active site; such allosteric effects have been frequently observed in protein footprinting experiments (14–17, 31).

Analyzing the dose-response curves for the other tryptic peptides as well as chymotryptic peptides obtained from free AVP, AVP-DNA, AVP-pVIc, and AVP-pVIc-DNA molecule illustrates the significant changes in the rate of modification (both increases and decreases) upon cofactor binding to the AVP molecule for many peptides (Table I, Supplemental Table I, Fig. 3). The modification rate data for all nine tryptic peptides of AVP and the AVP-pVIc-DNA ternary complex as well as that for six chymotryptic peptides are shown in bar graph format in Fig. 3.

N-terminal Segments of AVP—In free AVP, the N-terminal tryptic peptide (residues 1–9) had a modification rate of 11.2 s⁻¹, consistent with the peptide containing a highly accessible methionine residue (Table I). There was over a 90% decrease in reactivity for this peptide upon DNA binding in either the binary or ternary complex. Due to poor MS signals for peptide 1–9 in the AVP-pVIc binary complex, we were unable to determine its rate of modification. Chymotryptic peptide 16–21 (GGCPYF) showed no change in its modification rate on cofactor binding and a low rate of modification overall from ~0.5–0.6 s⁻¹ (Fig. 3), indicating that the probe residues in this segment were relatively buried and that they did not become more or less exposed upon AVP binding to its cofactors. Tryptic peptide 29–37 showed no change (within error) in its modification rate when free AVP was compared with its binary and ternary complexes (Table I, Fig. 3).

Allosteric Effects of Cofactor Binding in the Active Site Cleft—Tryptic peptide 38–48 had a very large modification rate in free AVP that is not consistent with the calculated surface area of Leu38 or Cys40. LC-coupled MS analysis showed considerable abundance of doubly oxidized peptide (560.8 m/z) at short exposure times relative to that of singly oxidized peptide (552.8 m/z). This indicated the oxidation of Cys40 in the peptide; tandem MS analysis (data not shown) confirmed Cys40 as the probe residue in free AVP. The rate of
modification increased 2-fold on binding pVlc, while it was unchanged upon binding to DNA, indicating that Cys40 became more reactive due to allosteric effects of peptide binding. Calculation of the rate of modification for the ternary complex was difficult due to the existence of a very large level of background oxidation for Cys40 at zero exposure time. LC-ESI-MS analysis showed free AVP had 1% of oxidized Cys40 at 0 ms exposure time. However, for the AVP-DNA-pVlc complex, >50% Cys40 was found to be oxidized without any exposure to x-rays. The chemical reactivity of Cys40 was higher than would be expected from its predicted buried surface area, and it was significantly increased by peptide binding. Its reactivity to air oxidation in the ternary complex was extraordinary.

Peptide 49–63, like peptide 38–48, became more reactive upon peptide binding but it also became more reactive upon binding DNA. These results were indicative of allosteric effects upon binding of either cofactor. Tandem MS was carried out to identify the site(s) of oxidation for peptide 49–63 (ETGGVHWMFAWNPR) to specifically identify the probe residue experiencing conformational changes. In tandem experiments a specific peptide fragment is selected by the first stage of the mass spectrometer for CID in the second stage (see Supplemental Fig. 2). The masses of the generated fragment peptides were measured and the site of fragmentation was determined by the observed masses of the fragments. When an oxidized fragment is selected in the first stage and fragmentated, the fragments that retain the mass shift are indicated to contain the original probe residue. For peptide 49–63, MS/MS analysis showed that potential probes Trp55 or Met56 were not oxidized in free AVP; the modified residue in free AVP was Trp60 because a y4+16-NH3 ion with minimal y4 was observed and b8 was seen to be predominantly unmodified (SF2). MS/MS analysis of same peptide in the ternary complex had a similar pattern, with the exception that a b9 ion was observed, indicating that Trp55 or Met56, in addition to Trp60, was oxidized upon cofactor binding. Thus, the former residues became more solvent-accessible upon cofactor binding.

**Peptides Protected on DNA Binding**—Peptide 82–93 (QVYQFEYESLLR) has multiple residues that could possibly give rise to oxidation (Table I). MS/MS sequencing was carried out on free AVP and its complex to determine the oxidation site(s) (data not shown). The y-type ions identified supported Phe86 as the primary oxidation site. The rate of modification of 1.2 s⁻¹ thus corresponded to the oxidation of a slightly solvent accessible Phe86 residue, which is almost entirely buried upon DNA binding. For tryptic peptide 95–103, virtually 100% protection was observed upon DNA binding in the binary or ternary complex, while pVlc binding increased the modification rate about 2-fold. Thus, this peptide was located at a site of potential DNA binding as well as a site of allosteric conformational change induced by peptide binding. MS/MS data clearly identifies Pro101 as the probe residue (data not shown). Within peptide 104–109, Cys104 forms a disulfide bond with the pVlc cofactor. The rate of modification of this peptide in free AVP was large (30.7 s⁻¹), consistent
with the high solvent accessibility of Cys\textsuperscript{104} (74 Å\textsuperscript{2}) and Leu\textsuperscript{107} (35 Å\textsuperscript{2}) in the absence of peptide. Upon pVlc binding, Cys\textsuperscript{104} and Leu\textsuperscript{107} become protected, with solvent accessible surface areas reduced to 15 and 1 Å\textsuperscript{2}, respectively, while the rate of modification was reduced by \(~85\%\). In addition, DNA binding showed a \(~75\%\) protection of this peptide. Unfortunately, tandem MS data could not be obtained for this peptide; however, Cys\textsuperscript{104} and Leu\textsuperscript{107} represent the likely probe sites.

C-terminal Peptide Interactions with Peptide and DNA Co-factors—Chymotryptic peptide 142–147 showed a significant decrease in the rate of modification on pVlc binding (Fig. 3, ST1). Protection of peptide 142–147 is consistent with the x-ray structure where Met\textsuperscript{147} is seen to interact with the N terminus of the pVlc peptide (Fig. 1a). Two peptides near the N terminus of AVP in D2 detected by MS were tryptic peptides 170–180 and 181–186. These peptides showed similar trends in their modification rates compared with peptides 82–93 and 95–103. Peptides 170–180 and 181–186 showed virtually 100% protection from modification when DNA was bound but experienced no changes in modification rate upon pVlc binding alone. These results are consistent with burial of their probe residues upon DNA binding. For peptide 170–180, MS/MS analysis of doubly charged, singly oxidized peptide indicated Tyr\textsuperscript{175} as the probe site, while for peptide 181–186, tandem data indicated Pro\textsuperscript{183} was the primary probe residue.

DISCUSSION

AVP contains two domains (D1 and D2) with the active site located in a cleft formed by the interacting surfaces of the subdomains (Fig. 1a). Active site residues His\textsuperscript{54}, Glu\textsuperscript{71}, and Cys\textsuperscript{122}, which are located deep within this cleft, are entirely conserved in a multiple alignment analysis of 26 sequences using ClustalW (Glu\textsuperscript{71} can be an Asp residue, SF1). The positions of these three residues in AVP can be superimposed on the active site of the archetypical cysteine proteinase papain, and this has led to the hypothesis that AVP and papain utilize a similar catalytic mechanism (7, 11, 32–34). His\textsuperscript{54} and Cys\textsuperscript{122}, the active site nucleophile of AVP, which may form an ion pair, are located on opposite subdomains. Thus, the enzyme’s activity is dependent on the relative positioning of the two domains. The bound pVlc cofactor bridges the subdomains; thus, the molecular mechanism by which it activates AVP may involve reorienting the subdomain interface.

pVlc-AVP Binding—The interactions of AVP and pVlc are well understood from the 1.6 Å resolution crystal structure of AVP-pVlc complex and include hydrogen bonds, ion pair interactions, van der Waals interactions, and a disulfide bond (5–7, 11). The solution footprinting data is entirely consistent with these crystallographic predictions, as peptide 104–109, which contains the disulfide bonded Cys\textsuperscript{104} as well as Leu\textsuperscript{107},
experiences a 4-fold decrease in reactivity upon pVIc binding to AVP, consistent with the significant reductions in solvent accessibility predicted from the crystallographic data (Table I, Fig. 4, a and b). Cys104 is absolutely conserved in all known AVP sequences while Leu107 is preferred. Within peptide 142–147, the highly conserved Met147 in domain D2 forms an interdomain hydrogen bond with the entirely conserved Gly17 at the N terminus of pVIc. This peptide also experiences a protection in the AVP-pVIc binary complex consistent with this interaction. This protection is shown in Fig. 4, a and b. In Fig. 4a, the peptides exhibiting DNA-dependent protections are colored in red, while the pVIc-dependent protections are colored pink. Peptides exhibiting DNA- or pVIc-dependent enhancements in reactivity are colored in blue. Fig. 4b illustrates the probe residues for each of these peptides.

**Cofactor-induced Conformational Changes**—Biochemical studies show that the two cofactors, pVIc and DNA increase the $k_{\text{cat}}$ for substrate hydrolysis and decrease the $K_m$ (8). The $k_{\text{cat}}$ for AVP increases by 117-fold due to the presence of pVIc, whereas the $K_m$ decreases 10-fold. For DNA binding to AVP, the effect on $k_{\text{cat}}$ and $K_m$ is about equal, with an 11-fold increase and a 10-fold decrease, respectively. The increased rates of modification for peptides 38–48 and 49–63 upon cofactor binding indicated increased “spatial” availability of the cleft to substrates as well as changes in the chemical reactivity of residues within the cleft. The reactivity of peptide 38–48 was not influenced by DNA binding alone but exhibited a 2-fold increased reactivity upon binding pVIc (Fig. 4, a and b). However, in the ternary complex, Cys10 was extraordinarily sensitive to oxidation, even by air. Within peptide 38–48, Thr45 is predicted to be hydrogen bonded to His54, which has a relationship to Cys122 similar to that seen in papain; the negatively charged Cys122 is ion paired to protonated His54, generating a very active nucleophilic species (33, 34). As the $k_{\text{cat}}$ of the enzyme is increased nearly 1,300-fold by the binding of both cofactors, it may be the case that the Cys122 ion pair is not formed until one or both cofactors bind enzyme. The extraordinary changes in reactivity of Cys40 imply that it may be involved (or sensitive to) the charge relay network that promotes ion-pair formation in the ternary complex.

Peptide 49–63, like 38–48, lines the interdomain active site cleft. Unlike peptide 38–48, its reactivity increased upon either DNA binding (2-fold) or pVIc binding alone (6-fold). For free AVP, Trp50 was the sole probe residue, while in the ternary complex, Trp55 and Met66, which are within 5 Å of the active site His54 and Cys122 residues, became more solvent accessible and were oxidized. Trp50 and Trp55 are conserved, primarily to preserve the architecture of the binding pocket. These data provide convincing evidence that cofactor binding to AVP changed the structure at the active site. In the case of pVIc binding, a possible molecular explanation for this reactivity change includes subdomain rearrangements mediated by interactions of the pVIc peptide across the interface between domains 1 and 2 (Fig. 1a). This raises the question as to the molecular mechanisms by which DNA binding provides a similar activation, as well as how the two cofactors work together to provide maximal activity for the enzyme.

**Nonspecific Binding of DNA to AVP**—The surface charges of AVP are shown in Fig. 1b (11); a number of positively charged surface patches are indicated in blue that could be potential interaction sites with the negatively charged DNA backbone. Many examples of sequence-specific interactions of DNA with DNA-binding proteins are known (35–39); fewer examples illustrate the nature of nonspecific recognition of ssDNA by proteins (40–45). In general, many DNA-protein interactions are in part mediated by long-range columbic interactions that bring the DNA into close proximity to the protein forming a “loose” dynamic complex (40). After this nonspecific binding, which is well preceded in the case of restriction enzymes (46), specific binding then can occur at the cognate site mediated by the formation of charge-charge interactions, specific hydrogen bonding, van der Walls contacts, and base stacking interactions (35–37, 40, 45, 47). The footprinting data clearly indicated DNA-dependent protections for five peptides (Fig. 4, a and b), where the extent of protection (≥90%) was consistent with burial of the respective probe sites in a macromolecular interface (12–14, 30). However, ligand-induced reorganization of structure may also contribute to burial of these residues (15–17, 31). The buried probe residues are indicated in Fig. 4b and include Met1, Pro183, and Tyr175 in D2, which are located on the opposite side of the molecule to Phe and Pro101 in D1. Because the stoichiometry of DNA-AVP binding is 1:1 for the 12-mer ssDNA used here (8), we considered the possibility that the DNA could be stretched across the AVP molecule so as to bury residues within both D1 and D2.

**Detailed Model of DNA-AVP Interactions**—The DNA-AVP interface was modeled using a 12-mer ssDNA with the sequence GACGACTAGGAT. The constraints in the modeling included DNA-dependent protection of the above probe residues, satisfaction of potential favorable charge or base stacking interactions, use of conserved residues to provide the trace of the DNA-AVP interaction, and reasonable constraints on the bond lengths and angles of the macromolecules. The final model (Fig. 5, a and b) satisfies many of these constraints, in particular solvent accessibility calculations; the coordinates of the ternary complex compared with that of the AVP-pVIc binary complex showed DNA-dependent protections from solvent for Phe86, Pro101, Pro183, and Tyr175.

In domain D1, the well-conserved, basic amino acid residues Lys51 on H2, Arg93 on H3, and Arg103 on S5 from AVP and Lys6, Arg7, Arg8, and Arg9 from pVIc provide charge interactions with the DNA. DNA binds to AVP much more tightly when pVIc is bound, suggesting specific interactions between cofactor peptide and DNA. Such interactions and the binding of DNA in this region (as predicted by the model) can be indirectly supported by the footprinting analysis of peptide 104–109. In absence of pVIc, this peptide was 4-fold pro-
tected upon DNA binding, strongly indicating that DNA binds to this segment of free AVP. DNA binding to D1 can be further stabilized by base stacking interactions with the solvent-exposed, highly conserved Tyr88 near the beginning of H3 in AVP and Phe11/H1103 from pVIc (Fig. 5a). The model does not predict specific interactions with Phe 86 on the loop connecting H2 and H3; however, the model predicts a significant reduction of solvent accessibility for this residue upon DNA binding consistent with the observed DNA-dependent protection (Table I).

In domain D2, residues Arg168 and Arg180 that span H5, His181 found between H5 and H6, Arg186 on H6, and Arg193 on H7 provide ionic interactions with DNA as well as H-bonding interactions. Of these residues, Arg193 is strongly conserved, but the vast majority of substitutions for all these residues are charged or polar. DNA binding to domain 2 can be stabilized by base stacking with surface-exposed Tyr175 on H5 within a hydrophobic cleft created by Tyr175 and Phe185; these two residues are entirely conserved. Additional interactions that can further stabilize the DNA can be mediated through Arg93 and Lys66 in domain D1 and His131 and Trp136 in the loop joining H4 and S6 in domain D2. Because no DNA-dependent protections were observed in these regions, binding to these residues may be dominated by water-mediated hydrogen-bonding interactions (41). The model does not directly explain the DNA-dependent protection of Met1; DNA-dependent subunit reorientation may induce an allosteric change that results in protection of this residue.

Although this model of DNA binding was constructed based on predicted interactions with a 12-mer ssDNA, we suggest that it provides a general model of AVP-DNA binding. AVP binds longer single-stranded sequences than a 12-mer and, in vivo, binds to double-stranded DNA. The model predicts a significant bending of the ssDNA, which is obviously quite flexible. However, bending of double-stranded DNA in the process of protein binding is well preceded. The co-crystal structure of Integration Host Factor bound to its specific binding site (the so-called H' site) shows the DNA wrapped around the protein in a U-turn that exceeds 180° (48). TATA-binding protein (TBP) binding to DNA also induces kinks in the DNA sequence where the TATA box sequences interact with the concave surface of TBP by bending toward the major groove, producing a wide open minor groove. Phenylalanine residues from TBP provide specific base-stacking interactions with the DNA (49–51). Based on these considerations, it is reasonable that the combination of conserved positively charged patches on AVP and its conserved aromatic residues that are poised for base-stacking interactions provides a facile surface for binding and bending double-stranded DNA. Thus, our model provides an overall framework for predicting
DNA Provides a Molecular Strap Activating AVP

AVP-DNA interactions and suggests that DNA binding provides a molecular strap reorienting the positions of the two subdomains directly influencing the reactivity of the active site. In addition, both pVlc and DNA may independently provide this reorientation as well as drive it cooperatively to fully activate AVP.

CONCLUSIONS

Synchrotron protein footprinting was used to determine the structural changes within AVP upon formation of complexes with its activating cofactors. The data revealed cofactor-dependent conformational changes at the catalytic site related to functional activation. Footprinting data of the binary complex of AVP with DNA as well as the ternary complex of AVP and both of its cofactors revealed potential sites of DNA contact with AVP on both domains of the molecule adjacent to conserved patches of positive charge. A molecular model of the AVP-DNA-pVlc ternary complex is proposed that is consistent with the footprinting data and the observed sequence conservation, as well as providing a molecular mechanism of activation that explains the synergistic effects of the two cofactors.

Acknowledgments—We thank M. L. Baniecki for assistance in some of the preliminary experiments.

* This research is supported in part by The Biomedical Technology Centers Program of the National Institute for Biomedical Imaging and Bioengineering (P41-EB-01979, M. R. C.), the Innovative Molecular Analysis Technologies Program of the National Cancer Institute (R33-CA-83179, M. R. C.), the Office of Biological and Environmental Research of the U.S. Department of Energy under Prime Contract DE-AC0298CH10886 with Brookhaven National Laboratory (W. F. M.), and by National Institutes of Health Grant AI41599 (W. F. M.). J. L. P. and both of its cofactors revealed potential sites of DNA contact with AVP. The data revealed cofactor-dependent conformational changes at the catalytic site related to functional activation. Footprinting data of the binary complex of AVP with DNA as well as the ternary complex of AVP and both of its cofactors revealed potential sites of DNA contact with AVP on both domains of the molecule adjacent to conserved patches of positive charge. A molecular model of the AVP-DNA-pVlc ternary complex is proposed that is consistent with the footprinting data and the observed sequence conservation, as well as providing a molecular mechanism of activation that explains the synergistic effects of the two cofactors.

REFERENCES

1. Weber, J. M., and Anderson, C. W. (1988) Identification of the gene coding for the precursor of adenovirus core protein K. J. Virol. 62, 1741–1745
2. Weber, J. (1976) Genetic analysis of adenovirus type 2 III. Temperature sensitivity of processing viral proteins. J. Virol. 17, 462–471
3. Webster, A., and Kemp, G. (1993) The active adenovirus protease is the intact L3 23K protein. J. Gen. Virol. 74, 1415–1420
4. Webster, A., Hay, R. T., and Kemp, G. (1993) The adenovirus protease is activated by a virus-coded disulphide-linked peptide. Cell 72, 97–104
5. Mangel, W. F., McGrath, W. J., Toledo, D. L., and Anderson, C. W. (1993) Viral DNA and a viral peptide can act as cofactors of adenovirus viron protease activity. Nature 361, 274–275
6. Baniecki, M. L., McGrath, W. J., McWhirter, S. M., Li, C., Toledo, D. L., Pellicena, P., Barnard, D. L., Thorn, K. S., and Mangel, W. F. (2001) Interaction of the human adenovirus protease with its 11-amino acid cofactor pVlc. Biochemistry 40, 12349–12356
7. McGrath, W. J., Ding, J., Didwania, A., Sweet, R. M., and Mangel, W. F. (2003) Crystallographic structure at 1.6 A resolution of the human adenovirus protease in a covalent complex with its 11-amino-acid-derivative cofactor: insights on a new fold. Biochim. Biophys. Acta 1648, 1–11
8. McGrath, W. J., Baniecki, M. L., Li, C., McWhirter, S. M., Brown, M. T., Toledo, D. L., and Mangel, W. F. (2001) Human adenovirus protease: DNA binding and stimulation of protease activity by DNA. Biochemistry 40, 13237–13245
9. McGrath, W. J., Baniecki, M. L., Peters, E., Green, D. T., and Mangel, W. F. (2001) Roles of two conserved cysteine residues in the activation of human adenovirus protease. Biochemistry 40, 14468–14474
10. Rancourt, C., Keyvan-Aminneh, H., Sircar, S., Labrecque, P., and Weber, J. M. (1995) Proline 137 is critical for adenovirus protease encaspitation and activation but not enzyme activity. Virology 209, 167–173
11. Ding, J., McGrath, W. J., Sweet, R. M., and Mangel, W. F. (1996) Crystal structure of the human adenovirus protease with its 11 amino acid cofactor. EMBO J. 15, 1778–1783
12. Guan, J. Q., Vorobiev, S., Almo, S. C., and Chance, M. R. (2002) Mapping the G-actin binding surface of cofillin using synchrotron protein footprinting. Biochemistry 41, 5755–5775
13. Rashidzadeh, H., Krapapov, S., Chance, M. R., and Brenowitz, M. (2003) Solution structure and interdomain interactions of the Saccharomyces cerevisiae “TATA Binding Protein” (TBP) probed by radiolytic protein footprinting. Biochemistry 42, 3655–3665
14. Liu, R., Guan, J. Q., Zak, O., Alsen, P., and Chance, M. R. (2003) Structural reorganization of transferin C-lobe and transferin receptor upon complex formation: C-lobe to the receptor helical domain. Biochemistry 42, 12447–12454
15. Guan, J. G., Almo, S. C., Reisler, E., and Chance, M. R. (2003) Structural reorganization of proteins revealed by radiolysis and mass spectrometry: G-actin solution structure is divergent cation dependent. Biochemistry 42, 11992–12000
16. Kiselar, J. G., Janmey, P. A., Almo, S. C., and Chance, M. R. (2003) Visualizing the Ca2+-dependent activation of gelsolin by using synchrotron footprinting. Proc. Natl. Acad. Sci. U. S. A. 100, 3942–3947
17. Kiselar, J. G., Janmey, P. A., Almo, S. C., and Chance, M. R. (2003) Structural analysis of gelsolin using synchrotron protein footprinting. Mol. Cell. Proteomics 2, 1120–1132
18. Mangel, W. F., Toledo, D. L., Brown, M. T., Martin, J. H., and McGrath, W. J. (1996) Characterization of three components of human adenovirus proteinase activity in vitro. J. Biol. Chem. 271, 536–543
19. Jensen, D. E., Kelly, R. C., and von Hippel, P. H. (1976) DNA “melting” proteins. II. Effects of bacteriophage T4 gene 32-protein binding on the conformation and stability of nucleic acid structures. J. Biol. Chem. 251, 7215–7228
20. Pace, C. N., Vajdos, F., Fee, L., Grimsley, G., and Gray T. (1995) How to measure and predict the molar absorption coefficient of a protein. Protein Sci. 4, 2411–2423
21. Ralston, C. Y., Sclavi, B., Sullivan, M., Deras, M. L., Woodson, S. A., Chance, M. R., and Brenowitz, M. (2000) Time-resolved synchrotron X-ray footprinting and its application to RNA folding. Methods Enzymol. 317, 353–368
22. Malekina, S. D., Ralston, C. Y., Brenowitz, M. D., Downard, K. M., and Chance, M. R. (2001) Determination of macromolecular folding and structure by synchrotron x-ray radiolysis techniques. Anal. Chem. 289, 103–115
23. Kiselar, J. G., Malekina, S. D., Sullivan, M., Downard, K. M., and Chance, M. R. (2002) Hydroxyl radical probe of protein surfaces using synchrotron x-ray radiolysis and mass spectrometry. Int. J. Radiat. Biol. 78, 101–114
24. Fraczkiewicz, R., and Braun, W. (1998) Exact and efficient analytical calculation of the accessible surface areas and their gradients for macro-molecules. J. Comput. Chem. 19, 319–333
25. Altschul, S. F., Madden, T. L., Schaffer, A. A., Zhang, J., Zhang, Z., Miller, W., and Lipman, D. J. (1997) Gapped BLAST and PSI-BLAST: A new generation of protein database search programs. Nucleic Acids Res. 25, 3389–3400
26. Thompson, J. D., Higgins, D. G., and Gibson, T. J. (1994) CLUSTAL W:
Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. *Nucleic Acids Res.* **22**, 4673–4680

27. Crooks, G., Hon, G., Chandonia, J. M., and Brenner S. E. (2004) Weblogo: A sequence logo generator. *Genome Res.* **14**, 1188–1190

28. Jones, T. A., Zou, J. Y., Cowan, S. W., and Kjeldgaard, M. (1991) Improved methods for building protein models in electron density maps and the location of errors in these models. *Acta Crystallogr.*, **A 47**, 110–119

29. Saenger, W. (1984) *Principles of Nucleic Acid Structure*, Springer-Verlag, New York.

30. Goldsmith, S. C., Guan, J. Q., Almo, S., and Chance, M. (2001) Synchrotron protein footprinting: A technique to investigate protein-protein interactions. *J. Biomol. Struct. Dyn.* **19**, 405–418

31. Guan, J. Q., Almo, S., and Chance, M. R. (2004) Synchrotron Radiolysis and Mass Spectrometry: A new approach to research on the actin cytoskeleton. *Acc. Chem. Res.* **37**, 221–229

32. Harrison, M. J., Burton, N. A., and Hillier, I. H. (1997) Catalytic mechanism of the enzyme papain: Predictions with a hybrid quantum mechanical/molecular mechanical potential. *J. Am. Chem. Soc.* **119**, 12285–12291

33. Storer, A. C., and Menard, R. (1994) Catalytic mechanism in papain family of cysteine peptidases. *Methods Enzymol.* **244**, 486–500

34. Barbezange, C., Benko, M., Dan, A., and Harrach, B. (2000) DNA sequencing and phyllogenetic analysis of the protease gene of ovine adenosivirus 3 suggest that adenosviruses of sheep belong to two different genera. *Virus Res.* **66**, 79–85

35. Peersen, O. B., Ruggles, J. A., and Schultz, S. C. (2002) Dimeric structure of the Oxytricha nova telomere end-binding protein alpha-subunit bound to ssDNA. *Nat. Struct. Biol.* **9**, 182–187

36. Theobald, D. L., and Schultz, S. C. (2003) Nucleotide shuffling and ssDNA recognition in Oxytricha nova telomere end-binding protein complexes. *EMBO J.* **22**, 4314–4324

37. Kerr, I. D., Wadsworth, R. I., Cubeddu, L., Blankenfeldt, W., Naismith, J. H., White, M. F. (2003) Insights into ssDNA recognition by the OB fold from a structural and thermodynamic study of Sulfolobus SSB protein. *EMBO J.* **22**, 2561–2570

38. Luscombe, N. M., Laskowski, R. A., and Thornton, J. M. (2001) Amino acid-base interactions: A three-dimensional analysis of protein-DNA interactions at an atomic level. *Nucleic Acids Res.* **29**, 2860–2874

39. Jones, S., van Heyningen, P., Bertram, H. M., and Thornton, J. M. (1999) Protein-DNA interactions: A structural analysis. *J. Mol. Biol.* **287**, 877–896

40. Sun, J., Viadali, H., Aggarwal, A. K., and Weinstein, H. (2003) Energetic and structural considerations for the mechanism of protein sliding along DNA in the nonspecific BamHI-DNA complex. *Biophys. J.* **84**, 317–325

41. Murphy, F. V., IV, and Churchill, M. E. (2000) Nonsequence-specific DNA recognition: A structural perspective. *Structure Fold Des.* **B**, R83–R89

42. Bochkarev, A., Pfluetzner, R. A., Edwards, A. M., and Frappier, L. (1997) Structure of the single-stranded-DNA-binding domain of replication protein A bound to DNA. *Nature* **385**, 176–181

43. Viadali, H., and Aggarwal, A. K. (2000) Structure of BamHI bound to non-specific DNA: A model for DNA sliding. *Mol. Cell* **5**, 889–895

44. Allain, F. H., Yen, Y. M., Masse, J. E., Schultz, P., Dieckmann, T., Johnson, R. C., and Feigon, J. (1999) Solution structure of the HMG protein NHP6A and its interaction with DNA reveals the structural determinants for non-sequence-specific binding. *EMBO J.* **18**, 2563–2579

45. Raghunathan, S., Kozlov, A. G., Lohman, T. M., and Waksman, G. (2000) Structure of the DNA binding domain of E. coli SSB bound to ssDNA. *Nat. Struct. Biol.* **7**, 648–652

46. Pingoud, A., and Jeltsch, A. (2001) Structure and function of type II restriction endonucleases. *Nucleic Acids Res.* **29**, 3705–3727

47. Anderson, E. M., Halsey, W. A., and Wuttke, D. S. (2003) Site-directed mutagenesis reveals the thermodynamic requirements for single-stranded DNA recognition by the telomere-binding protein Cdc13. *Biochemistry* **42**, 3751–3758

48. Rice, P. A., Yang, S., Mizuuchi, K., and Nash, H. A. (1996) Crystal structure of an IHF-DNA complex: A protein-induced DNA U-turn. *Cell* **87**, 1295–1306

49. Kim, J. L., Nikolov, D. B., and Burley, S. K. (1993) Co-crystal structure of TBP recognizing the minor groove of a TATA element. *Nature* **365**, 520–527

50. Juo, Z. S., Chiu, T. K., Leiberman, P. M., Baikalov, I., Berk, A. J., and Dickerson, R. E. (1996) How proteins recognize the TATA box. *J. Mol. Biol.* **261**, 239–254

51. Kim, Y., Geiger, J. H., Hahn, S., and Sigler, P. B. (1993) Crystal structure of a yeast TBP/TATA-box complex. *Nature* **365**, 512–520